Title:Histone Deacetylase Inhibitors and Papillary Thyroid Cancer
Volume: 27
Issue: 18
Author(s): Eleftherios Spartalis*, Konstantinos Kotrotsios, Dimosthenis Chrysikos, Michael Spartalis, Stavroula A. Paschou, Dimitrios Schizas, Konstantinos Tsamakis, Dimitrios Dimitroulis, Theodore Troupis and Nikolaos Nikiteas
Affiliation:
- 2nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Medical School, Athens,Greece
Keywords:
Papillary thyroid cancer, histone, deacetylase, inhibitors, HDAC, thyroid cancer.
Abstract:
Background/Aim: Papillary Thyroid Cancer (PTC) is the most common type of endocrine malignancy.
Although PTC has an excellent prognosis, the recurrent or metastatic disease could affect patients' survival.
Recent studies show that Histone Deacetylase Inhibitors (HDACIs) might be promising anticancer agents
against PTC. The aim of this review is to evaluate the role of HDACIs as an additional modality in PTC treatment
and to depict the latest trends of current research on this field.
Materials and Methods: This literature review was performed using the MEDLINE database. The search strategy
included terms: “thyroid cancer”, “papillary”, “HDAC”, “histone”, and “deacetylase”.
Results: Agents, such as Suberoyl Anilide Hydroxamic Acid, Trichostatin A, Valproic Acid, Sodium butyrate,
Panobinostat, Belinostat, Romidepsin, CUDC907 and N-Hydroxy-7-(2-naphthylthio)-Hepanomide have shown
promising anti-cancer effects on PTC cell lines but fail to trigger a major response in clinical trials.
Conclusion: HDACIs have no significant effect as monotherapy against PTC, but further research needs to be
conducted in order to investigate their potential effect when used as an additional modality.
